Myeloma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 18 years or older
- People who are willing and able to provide written consent to participate
- People who have been diagnosed with multiple myeloma that has come back (relapsed) and is no longer responding to treatment (refractory)
- People who have already received at least three previous treatments for their multiple myeloma
- People whose disease has stopped responding to at least one treatment from each of these three groups: a type of drug called a proteasome inhibitor, a type of drug called an immunomodulatory agent, and a drug that targets a protein called CD38 (an anti-CD38 monoclonal antibody)
- People whose disease has been confirmed to be getting worse during or after their most recent treatment, based on established multiple myeloma response guidelines
- People who are expected to begin treatment with a drug called teclistamab as part of their regular medical care, or who have already started teclistamab no more than 14 days before the planned screening visit
Who may not be able to join:
- People who have previously taken part in a clinical trial involving teclistamab, whether in the treatment group or a comparison group, or who have received teclistamab through a special individual access program (Single Patient Request)
- People who started teclistamab treatment more than 14 days before the planned screening visit
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Michel Delforge, MD, PhD, UZ Leuven Gasthuisberg
Phone: +32 16 34 68 80
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Overall response rate
Can't join this trial?
Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.